U.S., Jan. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07352527) titled 'New Clinical Decision Support Score Based on Steroid Hormone Profiling in the Diagnosis of MACS' on Sept. 16, 2025.
Brief Summary: The recent development of quantitative steroid metabolome profiling could be of interest for the positive diagnosis of mild autonomous cortisol-secreting adenoma (MACS). The aim of the study is to develop a predictive model of MACS status or non-secreting adenoma (NSA) based on a panel of 19 serum steroids and three clinico-biological parameters (body mass index or BMI, fasting glycaemia, blood pressure) and to estimate its performance for the diagnosis of MACS in a cohort of patients followed in the end...